Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial.

Diabetes Ther · 2022 · PMC8776932 · PMID 34870792

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Patients receiving dulaglutide 0.75 mg had a numerically higher reduction in HbA1c from baseline than patients receiving glargine, although the differences did not reach statistical significance (ESM Fig. 3a).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.